The abstract is read at the publisher; the summary is JClub's.
In 478 patients with clinical high-risk WHO grade 2 low-grade glioma, first-line radiotherapy versus dose-dense temozolomide showed no significant difference in progression-free survival or overall survival.
- Why it matters: Late toxicity and long survival make it crucial to know whether single-modality treatment choices meaningfully change outcomes, and whether molecular markers predict differential benefit.
- What they did: Patients were randomized to standard radiotherapy (28 × 1.8 Gy) or dose-dense temozolomide (75 mg/m2 daily for 21/28 days, up to 12 cycles), with post hoc molecular reclassification in 73% (351/478) using 2021 WHO criteria.
- The result: Astrocytoma with IDHmt/1p/19q noncodeletion had similar median OS (6.6–6.7 years) across arms, oligodendroglioma with IDHmt/1p/19q codeletion had OS 12.9 vs 14.9 years (HR 0.88, P = .63), and tumors without IDH mutations favored TMZ (OS 2.5 vs 4.7 years; HR 0.47, P = .0068).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.